Literature DB >> 2428820

A model study of the use of monoclonal antibodies in capture enzyme immunoassays for antigen quantification exploiting the epitope map of tick-borne encephalitis virus.

F X Heinz, W Tuma, F Guirakhoo, C Kunz.   

Abstract

On the basis of an epitope model, capture enzyme immunoassay systems using monoclonal antibodies have been devised for the detection and quantification of Tick-borne encephalitis virus and compared with a reference system employing polyclonal sera. Monoclonal antibodies were used both as capture and detector antibodies, their suitability depending primarily on their avidity and intrinsic background activity. A considerable increase in sensitivity was achieved by combining antibodies to different non-overlapping epitopes. Biotinylation of the detector antibodies allowed the construction of multiple site simultaneous binding assays. Furthermore the use of monoclonal antibodies of defined serological specificity made virus type identification possible. This assay can therefore be used as a rapid 'test of identity' as required during the manufacture of viral vaccines.

Mesh:

Substances:

Year:  1986        PMID: 2428820     DOI: 10.1016/0092-1157(86)90032-6

Source DB:  PubMed          Journal:  J Biol Stand        ISSN: 0092-1157


  30 in total

1.  Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E.

Authors:  S L Allison; K Stiasny; K Stadler; C W Mandl; F X Heinz
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Mutational evidence for an internal fusion peptide in flavivirus envelope protein E.

Authors:  S L Allison; J Schalich; K Stiasny; C W Mandl; F X Heinz
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence.

Authors:  Regina M Kofler; Franz X Heinz; Christian W Mandl
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Spontaneous mutations restore the viability of tick-borne encephalitis virus mutants with large deletions in protein C.

Authors:  Regina M Kofler; Agnes Leitner; Gabriel O'Riordain; Franz X Heinz; Christian W Mandl
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo.

Authors:  C W Mandl; H Kroschewski; S L Allison; R Kofler; H Holzmann; T Meixner; F X Heinz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

6.  Mimicking live flavivirus immunization with a noninfectious RNA vaccine.

Authors:  Regina M Kofler; Judith H Aberle; Stephan W Aberle; Steven L Allison; Franz X Heinz; Christian W Mandl
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

7.  Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line.

Authors:  Rainer Gehrke; Michael Ecker; Stephan W Aberle; Steven L Allison; Franz X Heinz; Christian W Mandl
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Two distinct size classes of immature and mature subviral particles from tick-borne encephalitis virus.

Authors:  Steven L Allison; Yizhi J Tao; Gabriel O'Riordain; Christian W Mandl; Stephen C Harrison; Franz X Heinz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.

Authors:  Judith H Aberle; Stephan W Aberle; Regina M Kofler; Christian W Mandl
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

10.  Construction and mutagenesis of an artificial bicistronic tick-borne encephalitis virus genome reveals an essential function of the second transmembrane region of protein e in flavivirus assembly.

Authors:  Klaus K Orlinger; Verena M Hoenninger; Regina M Kofler; Christian W Mandl
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.